-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VLWdvrBQOTPg92etRW7QqCUzn/Yse1sL+TqKFc6/LGSrm1oW0DoSBAfp7l8JXHyJ CK0f/+TXbJ1L4CNiYIodBw== 0000891092-04-004239.txt : 20040825 0000891092-04-004239.hdr.sgml : 20040825 20040825132223 ACCESSION NUMBER: 0000891092-04-004239 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040817 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20040825 DATE AS OF CHANGE: 20040825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSGENOMIC INC CENTRAL INDEX KEY: 0001043961 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 911789357 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30975 FILM NUMBER: 04995984 BUSINESS ADDRESS: STREET 1: 12325 EMMET ST CITY: OMAHA STATE: NE ZIP: 68164 BUSINESS PHONE: 4027385480 MAIL ADDRESS: STREET 1: 12325 EMMET STREET CITY: OMAHA STATE: NE ZIP: 68164 8-K 1 e18946-8k.htm FORM 8-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
August 17, 2004

TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)

Delaware   000-30975  
(State of Formation)   (Commission File Number)  

911789357
(IRS Employer Identification Number)

12325 Emmet Street      
Omaha, NE   68164  
(Address of principal executive offices)   (Zip Code)  

(402) 452-5400
(Registrants’ telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

 
   

 

Item 5.02. Appointment of Principal Officers.

        Effective August 17, 2004, Transgenomic’s Board of Directors appointed Michael A. Summers to the position of chief financial officer. Mr. Summers replaces interim CFO Mitchell L. Murphy, who remains with the Company in the capacity of vice president, secretary and treasurer. Mr. Summers’ previous experience includes ten years in public accounting and five years at publicly traded companies. In addition, John L. Allbery, former executive vice president of Operations with primary responsibility for oversight of the Company’s Nucleic Acids Business Segment, has left the Company to pursue other opportunities.

 
  2 

 

SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     TRANSGENOMIC, INC  
       
       
By   /s/ Mitchell L. Murphy  
   
 
    Mitchell L. Murphy, VP, Secretary & Treasurer  
   

August 25, 2004

 
  3 

 

-----END PRIVACY-ENHANCED MESSAGE-----